Drug Profile
Research programme: type-II DNA topoisomerase inhibitors - CEAMED
Alternative Names: TOPINIBLatest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator CEAMED
- Class Antineoplastics
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Cancer in Spain (unspecified route) before September 2023
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Spain
- 15 Jul 2016 Preclinical trials in Cancer in Spain (unspecified route)